Australia markets closed

T2 Biosystems, Inc. (TTOO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.3000-0.0100 (-0.76%)
At close: 4:00PM EDT

1.3200 +0.02 (1.54%)
Before hours: 8:52AM EDT

T2 Biosystems, Inc.

101 Hartwell Avenue
Lexington, MA 02421
United States
781 761 4646
http://www.t2biosystems.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees118

Key executives

NameTitlePayExercisedYear born
Mr. Alec BarclayChief Operations Officer477.4kN/A1981
Mr. John J. Sperzel IIIPres, CEO & DirectorN/AN/A1964
Dr. Tyler E. JacksCo-FounderN/AN/A1961
Mr. Lee JosephsonCo-Founder & Member of Scientific Advisory BoardN/AN/AN/A
Mr. John M. Sprague CPAChief Financial OfficerN/AN/A1959
Mr. Michael Terrence GibbsVP, Gen. Counsel & Corp. Sec.N/AN/A1971
Ms. Kelley MorganVP of HRN/AN/AN/A
Mr. Anthony PareChief Commercial OfficerN/AN/AN/A
Ms. Sandy J. Estrada Pharm.D.VP of Medical AffairsN/AN/AN/A
Dr. Joanne SpadoroConsultantN/AN/A1959
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it is developing Candida Auris, a multi-drug resistant pathogen; T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; and T2Lyme for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Corporate governance

T2 Biosystems, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.